Randomized Trialhigh evidence
Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial.
The Lancet. Respiratory medicine·May 1, 2024·PMID 38272050
Why it mattersVAP drives prolonged ICU stays and antibiotic overuse. This trial provides high-quality evidence that a pragmatic, individualized short-course strategy is safe and reduces antibiotic exposure and side-effects, supporting antimicrobial stewardship in both high- and low-resource settings.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled